Published in South Med J on October 01, 1979
In vitro studies with 5-fluorocytosine. Appl Microbiol (1969) 8.01
Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1991) 6.17
A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med (1999) 6.08
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
RNA packaging. Curr Top Microbiol Immunol (1996) 4.88
Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet (2000) 4.57
The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell (1995) 4.13
beta-Lactamase proceeds via an acyl-enzyme intermediate. Interaction of the Escherichia coli RTEM enzyme with cefoxitin. Biochemistry (1980) 3.94
Rationally and empirically derived dimensions of children's symptomatology: expert ratings and confirmatory factor analyses of the CBCL. J Consult Clin Psychol (2001) 3.45
In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin. J Antimicrob Chemother (1980) 3.33
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Kinetic studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid. Biochemistry (1978) 2.66
In vitro activity of 5-fluorocytosine against Candida and Torulopsis species. Antimicrob Agents Chemother (1973) 2.54
Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R41,400. J Infect Dis (1978) 2.51
In vitro antifungal activity of clotrimazole (Bay b 5097). Infect Immun (1971) 2.48
Inactivation of the RTEM beta-lactamase from Escherichia coli. Interaction of penam sulfones with enzyme. Biochemistry (1981) 2.47
Bioassay for hamycin and amphotericin B in serum and other biological fluids. Appl Microbiol (1969) 2.23
Group A rotaviruses produce extrahepatic biliary obstruction in orally inoculated newborn mice. Pediatr Res (1993) 2.22
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med (1987) 2.20
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
Chemical studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid. Biochemistry (1978) 2.12
Retinal degeneration in mice lacking the gamma subunit of the rod cGMP phosphodiesterase. Science (1996) 2.11
Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity (1998) 2.11
In vitro studies with combinations of 5-fluorocytosine and amphotericin B. Antimicrob Agents Chemother (1975) 2.10
Biological reactions to wear debris in total joint replacement. Proc Inst Mech Eng H (2000) 2.06
Cloning, characterization, and development expression of a rat lung alveolar type I cell gene in embryonic endodermal and neural derivatives. Dev Biol (1995) 2.05
E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci U S A (1999) 2.05
The influence of loading time and lubricant on the friction of articular cartilage. Proc Inst Mech Eng H (1996) 1.98
Bicycle-riding circumstances and injuries in school-aged children. A case-control study. Arch Pediatr Adolesc Med (1997) 1.92
Microseparation of the centers of alumina-alumina artificial hip joints during simulator testing produces clinically relevant wear rates and patterns. J Arthroplasty (2000) 1.90
Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis (1975) 1.88
New method for susceptibility testing with antifungal agents. Antimicrob Agents Chemother (1975) 1.83
Role of the melanocortin-4 receptor in metabolic rate and food intake in mice. Transgenic Res (2000) 1.83
In vitro and in vivo studies with BL-S786, cefoxitin, and cefamandole. Antimicrob Agents Chemother (1978) 1.82
In-vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia (1985) 1.76
Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia. Chest (1994) 1.71
Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology (Oxford) (2000) 1.67
The influence of design, materials and kinematics on the in vitro wear of total knee replacements. J Biomech (2005) 1.66
The cerebrovascular response to carbon dioxide in humans. J Physiol (2011) 1.66
Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med (1987) 1.65
Predictors of in-hospital mortality after DC catheter ablation of atrioventricular junction. Results of a prospective, international, multicenter study. Circulation (1991) 1.64
Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Br J Rheumatol (1986) 1.64
In vitro susceptibility of Cryptococcus neoformans to amphotericin B, hamycin, and 5-fluorocytosine. Antimicrob Agents Chemother (Bethesda) (1968) 1.62
Non-disjunction of chromosome 18. Hum Mol Genet (1998) 1.62
Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants. J Biol Chem (1999) 1.62
In vitro studies with miconazole and miconazole nitrate. J Antimicrob Chemother (1977) 1.61
In vitro activities of five oral cephalosporins against aerobic pathogenic bacteria. Antimicrob Agents Chemother (1977) 1.60
Polyethylene particles of a 'critical size' are necessary for the induction of cytokines by macrophages in vitro. Biomaterials (1998) 1.59
Job strain and prevalence of hypertension in a biracial population of urban bus drivers. Am J Public Health (1992) 1.59
The influence of continuous sliding and subsequent surface wear on the friction of articular cartilage. Proc Inst Mech Eng H (1999) 1.58
In vitro studies with cefazolin. Antimicrob Agents Chemother (1974) 1.55
Mechanical performance of clinically available, neonatal, high-frequency, oscillatory-type ventilators. Crit Care Med (1998) 1.53
In vitro and in vivo evaluation of antifungal agents. Eur J Clin Microbiol Infect Dis (1989) 1.52
The children of divorce parenting intervention: outcome evaluation of an empirically based program. Am J Community Psychol (1993) 1.49
In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother (1984) 1.48
Antifungal activity of 5-fluorocytosine as measured by disk diffusion susceptibility testing. J Infect Dis (1977) 1.47
The inefficiency of surgical masks for protection against droplet nuclei tuberculosis. J Occup Med (1991) 1.47
Wear of ultra-high molecular weight polyethylene acetabular cups in a physiological hip joint simulator in the anatomical position using bovine serum as a lubricant. Proc Inst Mech Eng H (1997) 1.46
A comparison of the wear and physical properties of silane cross-linked polyethylene and ultra-high molecular weight polyethylene. J Arthroplasty (2001) 1.46
Iron stores in pregnancy. Br J Haematol (1977) 1.46
In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst (1994) 1.45
Effect of size and dose on bone resorption activity of macrophages by in vitro clinically relevant ultra high molecular weight polyethylene particles. J Biomed Mater Res (2000) 1.42
Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells. J Immunol (1997) 1.42
Wear of polyethylene in artificial hip joints: superolateral wear of the acetabulum. J Bone Joint Surg Br (1998) 1.42
Characterization of antibodies to the rat substance P (NK-1) receptor and to a chimeric substance P receptor expressed in mammalian cells. J Neurosci (1994) 1.40
The Percutaneous Cardiac Mapping and Ablation Registry: final summary of results. Pacing Clin Electrophysiol (1988) 1.39
In vitro susceptibility testing with tobramycin. Antimicrob Agents Chemother (1972) 1.38
Subsets of CD8+, CD57+ cells in normal, healthy individuals: correlations with human cytomegalovirus (HCMV) carrier status, phenotypic and functional analyses. Clin Exp Immunol (1993) 1.38
New medium for in vitro susceptibility studies with amphotericin B. Antimicrob Agents Chemother (1976) 1.37
Rapid determination of serum 5-fluorocytosine levels by high-performance liquid chromatography. Antimicrob Agents Chemother (1978) 1.36
Quantitative analysis of wear and wear debris from metal-on-metal hip prostheses tested in a physiological hip joint simulator. Biomed Mater Eng (2001) 1.34
Dematiaceous fungal pathogens isolated from nature. Mycopathologia (1980) 1.33
Lateral sinus thrombosis and intracranial hypertension in essential thrombocythaemia. J Neurol Neurosurg Psychiatry (1986) 1.32
The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med (1981) 1.31
Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer (1993) 1.30
The effect of nano- and micron-sized particles of cobalt-chromium alloy on human fibroblasts in vitro. Biomaterials (2007) 1.28
Hypocalcemia due to hypomagnesemia and reversible parathyroid hormone unresponsiveness. J Clin Endocrinol Metab (1969) 1.28
N-formimidoyl thienamycin (MK0787): in vitro study. Antimicrob Agents Chemother (1981) 1.26
Evaluation of the response of primary human peripheral blood mononuclear phagocytes to challenge with in vitro generated clinically relevant UHMWPE particles of known size and dose. J Biomed Mater Res (2000) 1.22
Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J Infect Dis (1985) 1.22
5-fluorocytosine in human candidiasis. Antimicrob Agents Chemother (Bethesda) (1970) 1.22
Detection of candida antigenemia by counterimmunoelectrophoresis in patients with invasive candidiasis. J Infect Dis (1979) 1.20
In vitro activities of polyene and imidazole antifungal agents against unusual opportunistic fungal pathogens. Mycoses (1990) 1.20
Serotype B/C Cryptococcus neoformans isolated from patients in nonendemic areas. J Clin Microbiol (1982) 1.19
Urinary tract infections due to Candida albicans. Rev Infect Dis (1983) 1.19
Evaluation of a psycho-educational group programme for family caregivers in home-based palliative care. Palliat Med (2008) 1.19
Beta-lactamase inactivation by mechanism-based reagents. Philos Trans R Soc Lond B Biol Sci (1980) 1.17
Surfactant metabolism in SP-D gene-targeted mice. Am J Physiol Lung Cell Mol Physiol (2000) 1.16
The proapoptotic BCL-2 family member BIM mediates motoneuron loss in a model of amyotrophic lateral sclerosis. Cell Death Differ (2007) 1.15
Relationship of endomysial antibodies to jejunal mucosal pathology: specificity towards both symptomatic and asymptomatic celiacs. J Pediatr Gastroenterol Nutr (1989) 1.15
Influence of the meniscus on friction and degradation of cartilage in the natural knee joint. Osteoarthritis Cartilage (2009) 1.14
Therapeutic failures with miconazole. Antimicrob Agents Chemother (1978) 1.14
Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Pharmacol (1998) 1.14
The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes (2001) 1.14
Preparation, characterization, and chemical properties of the flavin coenzyme analogues 5-deazariboflavin, 5-deazariboflavin 5'-phosphate, and 5-deazariboflavin 5'-diphosphate, 5'leads to5'-adenosine ester. Biochemistry (1976) 1.13
Comparison of wear, wear debris and functional biological activity of moderately crosslinked and non-crosslinked polyethylenes in hip prostheses. Proc Inst Mech Eng H (2002) 1.13
Chemical and enzymatic properties of riboflavin analogues. Biochemistry (1978) 1.12
A new approach to template purification for sequencing applications using paramagnetic particles. Biotechniques (1992) 1.12
Biological effects of clinically relevant wear particles from metal-on-metal hip prostheses. Proc Inst Mech Eng H (2006) 1.12
Influence of admission body temperature on stroke mortality. Stroke (2000) 1.12